Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
Rothenburger T, Thomas D, Schreiber Y, Wratil PR, Pflantz T, Knecht K, Digianantonio K, Temple J, Schneider C, Baldauf HM, McLaughlin KM, Rothweiler F, Bilen B, Farmand S, Bojkova D, Costa R, Ferreirós N, Geisslinger G, Oellerich T, Xiong Y, Keppler OT, Wass MN, Michaelis M, Cinatl J Jr. Rothenburger T, et al. Among authors: oellerich t. J Exp Clin Cancer Res. 2021 Oct 12;40(1):317. doi: 10.1186/s13046-021-02093-4. J Exp Clin Cancer Res. 2021. PMID: 34641952 Free PMC article.
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C. Göllner S, et al. Among authors: oellerich t. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. Nat Med. 2017. PMID: 27941792 Free PMC article.
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr. Schneider C, et al. Among authors: oellerich t. Nat Med. 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255. Epub 2016 Dec 19. Nat Med. 2017. PMID: 27991919
Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr. Schneider C, et al. Among authors: oellerich t. Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a. Nat Med. 2017. PMID: 28586337 No abstract available.
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
Hoang VT, Verma D, Godavarthy PS, Llavona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Müller-Kuller U, Weissenberger E, Voutsinas JM, Oehler VG, Farin HF, Zörnig M, Krause DS. Hoang VT, et al. Among authors: oellerich t. Leukemia. 2019 Jul;33(7):1700-1712. doi: 10.1038/s41375-018-0358-8. Epub 2019 Jan 11. Leukemia. 2019. PMID: 30635626
Metabolic Plasticity of Acute Myeloid Leukemia.
Kreitz J, Schönfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, Steffen B, Schwalbe H, Schnütgen F, Kurrle N, Serve H. Kreitz J, et al. Among authors: oellerich t. Cells. 2019 Jul 31;8(8):805. doi: 10.3390/cells8080805. Cells. 2019. PMID: 31370337 Free PMC article. Review.
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, Schliemann C, Bohnenberger H, Angenendt L, Hartmann W, Wardelmann E, Rothenburger T, Mohr S, Scheich S, Comoglio F, Wilke A, Ströbel P, Serve H, Michaelis M, Ferreirós N, Geisslinger G, Xiong Y, Keppler OT, Cinatl J Jr. Oellerich T, et al. Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4. Nat Commun. 2019. PMID: 31375673 Free PMC article.
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, Pikman Y, Robichaud A, Goodale A, Häupl B, Mohr S, Rao AV, Walker AR, Blachly JS, Piccioni F, Armstrong SA, Byrd JC, Oellerich T, Stegmaier K. Cremer A, et al. Among authors: oellerich t. Cancer Discov. 2020 Feb;10(2):214-231. doi: 10.1158/2159-8290.CD-19-0209. Epub 2019 Nov 26. Cancer Discov. 2020. PMID: 31771968 Free PMC article.
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression.
Walker AR, Byrd JC, Blachly JS, Bhatnagar B, Mims AS, Orwick S, Lin TL, Crosswell HE, Zhang D, Minden MD, Munugalavadla V, Long L, Liu J, Pan Y, Oellerich T, Serve H, Rao AV, Blum WG. Walker AR, et al. Among authors: oellerich t. Clin Cancer Res. 2020 Nov 15;26(22):5852-5859. doi: 10.1158/1078-0432.CCR-20-1064. Epub 2020 Aug 20. Clin Cancer Res. 2020. PMID: 32820015 Clinical Trial.
100 results